Suh-Chin Wu

List of Publications by Year
in descending order

62 papers	1,740 citations	257450 24 h-index	302126 39 g-index
63 all docs	63 docs citations	63 times ranked	2380 citing authors

#	Article	IF	Citations
1	Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity. International Journal of Molecular Sciences, 2022, 23, 4902.	4.1	9
2	Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges. Pharmaceutics, 2022, 14, 1014.	4.5	6
3	Neuraminidase (NA) 370-Loop Mutations of the 2009 Pandemic H1N1 Viruses Affect NA Enzyme Activity, Hemagglutination Titer, Mouse Virulence, and Inactivated-Virus Immunogenicity. Viruses, 2022, 14, 1304.	3.3	1
4	Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections. Frontiers in Immunology, 2021, 12, 692700.	4.8	5
5	Production of Multi-Subtype Influenza Virus-Like Particles by Molecular Fusion with BAFF or APRIL for Vaccine Development. Methods in Molecular Biology, 2021, 2248, 139-153.	0.9	2
6	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 795741.	4.8	13
7	Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination. , 2020, 8, e001022.		13
8	Type IIb Heat Labile Enterotoxin B Subunit as a Mucosal Adjuvant to Enhance Protective Immunity against H5N1 Avian Influenza Viruses. Vaccines, 2020, 8, 710.	4.4	3
9	Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine. Vaccines, 2020, 8, 240.	4.4	7
10	A quantitative luciferase-based cellâ€"cell fusion assay to measure four-serotype dengue virus E protein-triggered membrane fusion. Human Vaccines and Immunotherapeutics, 2020, 16, 2176-2182.	3.3	6
11	Progress and Concept for COVIDâ€19 Vaccine Development. Biotechnology Journal, 2020, 15, e2000147.	3.5	75
12	Glycanâ€masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development. Biotechnology and Bioengineering, 2019, 116, 598-609.	3.3	14
13	Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Theranostics, 2019, 9, 4811-4826.	10.0	14
14	Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development. Vaccine, 2019, 37, 6933-6941.	3.8	10
15	Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development. Antiviral Research, 2019, 164, 12-22.	4.1	8
16	Highly Pathogenic Avian Influenza H5 Hemagglutinin Fused with the A Subunit of Type IIb Escherichia coli Heat Labile Enterotoxin Elicited Protective Immunity and Neutralization by Intranasal Immunization in Mouse and Chicken Models. Vaccines, 2019, 7, 193.	4.4	3
17	Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture. Vaccine, 2018, 36, 3134-3139.	3.8	11
18	Zika virus structural biology and progress in vaccine development. Biotechnology Advances, 2018, 36, 47-53.	11.7	75

#	Article	IF	Citations
19	Identification of Immunoreactive Peptides of Toxins to Simultaneously Assess the Neutralization Potency of Antivenoms against Neurotoxicity and Cytotoxicity of Naja atra Venom. Toxins, 2018, 10, 10.	3.4	12
20	Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development. Antiviral Research, 2017, 146, 213-220.	4.1	4
21	Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology. Antiviral Research, 2016, 132, 225-232.	4.1	11
22	Influenza Virus Hemagglutinin Glycoproteins with Different N-Glycan Patterns Activate Dendritic Cells In Vitro. Journal of Virology, 2016, 90, 6085-6096.	3.4	23
23	Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design. Antiviral Research, 2016, 133, 110-118.	4.1	8
24	Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design. Journal of Virology, 2016, 90, 8496-8508.	3.4	41
25	Development of single-chain variable fragments (scFv) against influenza virus targeting hemagglutinin subunit 2 (HA2). Archives of Virology, 2016, 161, 19-31.	2.1	17
26	Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Journal of Virology, 2015, 89, 7224-7234.	3.4	68
27	Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection. Vaccine, 2015, 33, 4321-4329.	3.8	26
28	Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses. PLoS ONE, 2015, 10, e0131240.	2.5	39
29	Glycan Masking of Hemagglutinin for Adenovirus Vector and Recombinant Protein Immunizations Elicits Broadly Neutralizing Antibodies against H5N1 Avian Influenza Viruses. PLoS ONE, 2014, 9, e92822.	2.5	43
30	Dengue Type Four Viruses with E-Glu345Lys Adaptive Mutation from MRC-5 Cells Induce Low Viremia but Elicit Potent Neutralizing Antibodies in Rhesus Monkeys. PLoS ONE, 2014, 9, e100130.	2.5	4
31	Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques. PLoS ONE, 2014, 9, e106756.	2.5	8
32	Glutamic Acid at Residue 125 of the prM Helix Domain Interacts with Positively Charged Amino Acids in E Protein Domain II for Japanese Encephalitis Virus-Like-Particle Production. Journal of Virology, 2014, 88, 8386-8396.	3.4	13
33	Heterologous primeâ€boost immunization regimens using adenovirus vector and virusâ€like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnology Journal, 2013, 8, 1315-1322.	3.5	11
34	Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans. PLoS ONE, 2013, 8, e66719.	2.5	37
35	Production of EV71 vaccine candidates. Human Vaccines and Immunotherapeutics, 2012, 8, 1775-1783.	3.3	64
36	Broader Neutralizing Antibodies against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated Hemagglutinin DNA and Virus-Like Particles. PLoS ONE, 2012, 7, e39075.	2.5	48

#	Article	IF	Citations
37	Using recombinant DNA technology for the development of live-attenuated dengue vaccines. Enzyme and Microbial Technology, 2012, 51, 67-72.	3.2	8
38	Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine, 2011, 29, 7163-7172.	3.8	22
39	Recombinant Trimeric HA Protein Immunogenicity of H5N1 Avian Influenza Viruses and Their Combined Use with Inactivated or Adenovirus Vaccines. PLoS ONE, 2011, 6, e20052.	2.5	48
40	Review of dengue virus and the development of a vaccine. Biotechnology Advances, 2011, 29, 239-247.	11.7	151
41	Production of Inactivated Influenza H5N1 Vaccines from MDCK Cells in Serum-Free Medium. PLoS ONE, 2011, 6, e14578.	2.5	35
42	Dengue Type 4 Live-Attenuated Vaccine Viruses Passaged in Vero Cells Affect Genetic Stability and Dengue-Induced Hemorrhaging in Mice. PLoS ONE, 2011, 6, e25800.	2.5	10
43	Generating stable chinese hamster ovary cell clones to produce a truncated SARSâ€CoV spike protein for vaccine development. Biotechnology Progress, 2010, 26, 1733-1740.	2.6	4
44	Detection of swine-origin influenza A (H1N1) viruses using a localized surface plasmon coupled fluorescence fiber-optic biosensor. Biosensors and Bioelectronics, 2010, 26, 1068-1073.	10.1	55
45	Characterization of the GXXXG motif in the first transmembrane segment of Japanese encephalitis virus precursor membrane (prM) protein. Journal of Biomedical Science, 2010, 17, 39.	7.0	19
46	Dendritic Cell Activation by Recombinant Hemagglutinin Proteins of H1N1 and H5N1 Influenza A Viruses. Journal of Virology, 2010, 84, 12011-12017.	3.4	34
47	RNA interference technology to improve recombinant protein production in Chinese hamster ovary cells. Biotechnology Advances, 2009, 27, 417-422.	11.7	29
48	Short hairpin RNA targeted to dihydrofolate reductase enhances the immunoglobulin G expression in gene-amplified stable Chinese hamster ovary cells. Vaccine, 2008, 26, 4969-4974.	3.8	13
49	High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero Cells. PLoS ONE, 2008, 3, e1810.	2.5	14
50	Artificial extracellular matrix proteins contain heparin-binding and RGD-containing domains to improve osteoblast-like cell attachment and growth. Journal of Biomedical Materials Research - Part A, 2006, 79A, 557-565.	4.0	8
51	Histidine at Residue 99 and the Transmembrane Region of the Precursor Membrane prM Protein Are Important for the prM-E Heterodimeric Complex Formation of Japanese Encephalitis Virus. Journal of Virology, 2005, 79, 8535-8544.	3.4	31
52	Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: Variations in virus titer, plaque morphology, and replication rate. Biotechnology and Bioengineering, 2004, 85, 482-488.	3.3	11
53	Novel Cell Adhesive Glycosaminoglycan-binding Proteins of Japanese Encephalitis Virus. Biomacromolecules, 2004, 5, 2160-2164.	5.4	14
54	Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization. Vaccine, 2004, 23, 163-171.	3.8	10

#	Article	IF	Citations
55	Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine, 2004, 22, 3858-3864.	3.8	67
56	Phenotypic and genotypic characterization of the neurovirulence and neuroinvasiveness of a large-plaque attenuated Japanese encephalitis virus isolate. Microbes and Infection, 2003, 5, 475-480.	1.9	8
57	The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine, 2003, 21, 2516-2522.	3.8	47
58	A Functional Epitope Determinant on Domain III of the Japanese Encephalitis Virus Envelope Protein Interacted with Neutralizing-Antibody Combining Sites. Journal of Virology, 2003, 77, 2600-2606.	3.4	91
59	Structural Basis of a Flavivirus Recognized by Its Neutralizing Antibody. Journal of Biological Chemistry, 2003, 278, 46007-46013.	3.4	108
60	Production of Retrovirus and Adenovirus Vectors for Gene Therapy: A Comparative Study Using Microcarrier and Stationary Cell Culture. Biotechnology Progress, 2002, 18, 617-622.	2.6	53
61	Neutralizing peptide ligands selected from phage-displayed libraries mimic the conformational epitope on domain III of the Japanese encephalitis virus envelope protein. Virus Research, 2001, 76, 59-69.	2.2	38
62	Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Research, 1997, 51, 173-181.	2.2	60